AUROVELA 1.5/30 Drug Patent Profile

« Back to Dashboard

Which patents cover Aurovela 1.5/30, and what generic alternatives are available?

Aurovela 1.5/30 is a drug marketed by Aurobindo Pharma and is included in one NDA.

The generic ingredient in AUROVELA 1.5/30 is ethinyl estradiol; norethindrone acetate. There is one drug master file entry for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; norethindrone acetate profile page.

Summary for AUROVELA 1.5/30

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	5
Patent Applications:	206
DailyMed Link:	AUROVELA 1.5/30 at DailyMed

Pharmacology for AUROVELA 1.5/30

Drug Class	Estrogen Progestin
Mechanism of Action	Estrogen Receptor Agonists

US Patents and Regulatory Information for AUROVELA 1.5/30

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Aurobindo Pharma	AUROVELA 1.5/30	ethinyl estradiol; norethindrone acetate	TABLET;ORAL-21	207581-001	Jun 26, 2017	AB	RX	No	No

AUROVELA 1.5/30 Market Dynamics, Patent Position, and Financial Trajectory

Last updated: October 3, 2026

Aurovela 1.5/30 is a generic combined oral contraceptive containing norethindrone acetate 1.5 mg and ethinyl estradiol 30 mcg. Aurobindo Pharma markets the product in the U.S. through its pharmaceutical subsidiaries. The product competes in a mature, multi-source contraceptive market with limited pricing power, no meaningful branded exclusivity, and low barriers to additional generic entry. Public sources do not disclose product-level revenue, prescription volume, margin, or market share for Aurovela 1.5/30. Its financial trajectory therefore must be assessed through generic-market structure, portfolio positioning, supply execution, and manufacturer-level performance.

What is Aurovela 1.5/30 and who manufactures it?

Aurovela 1.5/30 is an oral contraceptive tablet with:

Product attribute	Detail
Active ingredients	Norethindrone acetate 1.5 mg and ethinyl estradiol 30 mcg
Dosage form	Oral tablet
Therapeutic category	Combined hormonal contraceptive
U.S. regulatory pathway	Abbreviated New Drug Application, or ANDA
Manufacturer and marketer	Aurobindo Pharma group
Reference-product class	Loestrin 1.5/30 and equivalent norethindrone acetate/ethinyl estradiol products
Product type	Multi-source generic
U.S. prescription status	Prescription only
Federal exclusivity profile	No current new-drug exclusivity expected for this mature generic product

The formulation uses a progestin, norethindrone acetate, with an estrogen, ethinyl estradiol. Its clinical and commercial position is distinct from Aurovela Fe 1.5/30, which includes ferrous fumarate reminder tablets. Product selection can therefore depend on pack configuration, pharmacy substitution, prescriber preference, payer formulary placement, and patient tolerance.

The FDA-approved labeling identifies the product for prevention of pregnancy. As with other combined oral contraceptives, labeling includes contraindications and warnings relating to thromboembolic events, smoking in older patients, cardiovascular risk, hypertension, and other estrogen-associated risks. (DailyMed, 2024)

How large is the market for Aurovela 1.5/30?

Aurovela 1.5/30 participates in the broader U.S. oral contraceptive market rather than a protected product market. Demand is recurring because users typically refill monthly, but treatment persistence is affected by switching, insurance changes, side effects, adherence, pregnancy planning, and migration to long-acting reversible contraception.

The principal commercial competitors include:

• Generic norethindrone acetate/ethinyl estradiol 1.5 mg/30 mcg tablets from multiple manufacturers.
• Aurovela Fe 1.5/30.
• Blisovi 1.5/30 and Blisovi Fe 1.5/30.
• Junel 1.5/30 and Junel Fe 1.5/30.
• Microgestin 1.5/30 and Microgestin Fe 1.5/30.
• Generic and branded alternatives containing different progestins or estrogen doses.
• Progestin-only pills, intrauterine systems, implants, injections, patches, and vaginal rings.

The market is highly substitutable. Pharmacies and payers can move prescriptions among therapeutically equivalent generic suppliers when acquisition cost, availability, or wholesaler terms change.

What drives demand for Aurovela 1.5/30?

Demand is driven by:

1. Continued use of oral contraception among reproductive-age patients.
2. Generic substitution and formulary coverage.
3. Manufacturer supply reliability.
4. Retail pharmacy and mail-order availability.
5. Prescriber continuity for patients already stable on norethindrone acetate/ethinyl estradiol.
6. Relative cost compared with branded products and nonoral contraceptives.

Aurovela’s established product identity may support prescription continuity, but the molecule and dosage combination are not differentiated enough to create significant standalone pricing power.

What is the FDA regulatory status of Aurovela 1.5/30?

Aurovela 1.5/30 is regulated as an approved generic oral contraceptive under the ANDA pathway. FDA approval requires demonstration of pharmaceutical equivalence and bioequivalence to the applicable reference product, together with compliance with manufacturing and quality requirements.

The principal FDA commercial risks are not regulatory exclusivity risks. They are:

• Manufacturing observations or warning letters.
• Product recalls.
• Packaging or labeling errors.
• Temporary shortages.
• Failure to maintain acceptable quality metrics.
• Changes in supplier or manufacturing-site authorization.
• Discontinuation or inactive listing in FDA databases.

A product’s FDA approval does not guarantee continuous commercial supply. Generic manufacturers can retain approval while reducing distribution or discontinuing active marketing.

What patents protect Aurovela 1.5/30?

Aurovela 1.5/30 does not appear to have a meaningful product-specific patent estate comparable to a recently approved branded medicine. The active ingredients and dosage combination have been marketed for decades, and the original innovator exclusivity period has expired.

IP category	Aurovela 1.5/30 position
Composition-of-matter patent	No commercially relevant current protection identified
New-drug patent	No current branded patent barrier expected
Formulation patent	No material product-specific formulation estate identified
Method-of-use patent	No meaningful current exclusivity identified
Manufacturing patent	Potentially relevant to a supplier, process, or facility, but not generally a barrier to generic substitution
FDA marketing exclusivity	No current exclusivity expected
Orange Book patent listing	No material current listing expected to block generic competition

The FDA Orange Book is principally relevant to listed patents and exclusivity for approved drug products. For a mature, multi-source oral contraceptive, the economic question is usually whether a manufacturer can supply at acceptable cost rather than whether a patent blocks entry. (U.S. Food and Drug Administration, 2025a)

When does Aurovela 1.5/30 lose exclusivity?

Aurovela 1.5/30 has no commercially important remaining exclusivity period to lose. It is already positioned as a generic product in a competitive market.

There is no expected 180-day generic exclusivity advantage associated with the product’s ordinary commercial position. A Paragraph IV challenge would be relevant only if a listed patent protected a competing reference product or an associated formulation. The mature nature of the active ingredients makes a new Paragraph IV event for the basic Aurovela formulation commercially unlikely.

Are there Paragraph IV challenges or patent settlements?

No material Aurovela 1.5/30-specific Paragraph IV litigation or settlement agreement is publicly established in the principal FDA patent framework. The product’s commercial exposure is more likely to arise from routine generic competition, supply disruptions, pricing pressure, and portfolio decisions than from patent litigation.

No biosimilar risk applies. Aurovela is a small-molecule tablet, not a biologic. Competitors enter through ANDAs rather than the biosimilar pathway under the Public Health Service Act.

How strong is the patent estate for Aurovela 1.5/30?

The patent estate is weak from a defensive commercial perspective because the product depends on an old active-ingredient combination with multiple substitutable suppliers.

Its practical protection comes from operational factors:

• FDA-approved manufacturing capacity.
• Reliable active pharmaceutical ingredient sourcing.
• Retail and wholesale distribution.
• Pharmacy stocking relationships.
• Product availability during competitor shortages.
• Contract pricing.
• Aurobindo’s ability to maintain acceptable quality and supply.

These factors can produce temporary share gains but do not create durable exclusivity. A manufacturer that loses supply continuity can quickly lose volume to another approved generic.

What formulations are protected by Aurovela-related patents?

No significant proprietary formulation platform is associated publicly with standard Aurovela 1.5/30 tablets. The product is a conventional immediate-release oral tablet. Aurovela Fe 1.5/30 differs primarily in pack design and the inclusion of ferrous fumarate reminder tablets, not in the creation of a high-barrier delivery system.

The absence of an extended-release, transdermal, implantable, injectable, or device-based delivery system limits opportunities for formulation-based differentiation.

What is the financial trajectory for Aurovela 1.5/30?

Aurobindo does not report Aurovela 1.5/30 as a standalone revenue line in its public financial disclosures. Product-level revenue, gross margin, prescription count, and net price are therefore not available from company reporting. Aurobindo reports performance at broader business and geographic levels, including the U.S. formulations business. (Aurobindo Pharma Limited, 2024)

The likely financial trajectory has four stages:

Stage	Financial characteristics
Launch or relaunch	Higher initial gross-to-net potential if few approved suppliers are active
Early competition	Price declines as additional generic suppliers gain pharmacy and payer access
Mature supply	Stable but low-margin recurring volume; profitability depends on manufacturing cost
Late-cycle portfolio management	Possible discontinuation, reduced promotion, or retention as a low-cost catalog product

Aurovela 1.5/30 can generate useful recurring revenue if it retains prescription volume and avoids supply interruptions. Its contribution is unlikely to be material to Aurobindo’s consolidated financial results unless the product achieves unusually high share or benefits from a temporary shortage affecting competitors.

What could improve Aurovela’s economics?

The main upside drivers are:

• Competitor supply shortages.
• A reduction in active manufacturers.
• Strong payer placement.
• Lower manufacturing cost.
• Vertical integration of API supply.
• Higher utilization of Aurobindo’s U.S. distribution network.
• Stable demand from existing patients.
• Cross-selling within Aurobindo’s women’s-health portfolio.

These gains are generally reversible. Once competitors restore supply or cut prices, excess margin tends to contract.

What could weaken revenue?

The main downside drivers are:

• Additional generic approvals.
• Pharmacy substitution to lower-cost suppliers.
• Contract losses with wholesalers or managed-care organizations.
• Manufacturing deviations or recalls.
• API cost increases.
• Declining oral-contraceptive use in favor of long-acting methods.
• Product discontinuation by Aurobindo.
• Patient switching to Aurovela Fe, other norethindrone formulations, or unrelated contraceptives.

Which companies challenge Aurovela 1.5/30?

Competition comes from generic manufacturers and branded portfolio owners rather than from a single direct patent challenger. Relevant competitors include manufacturers associated with Junel, Blisovi, Microgestin, and other norethindrone acetate/ethinyl estradiol products.

The market is shaped by three competitive layers:

1. Same-strength generic equivalents.
2. Adjacent oral contraceptives using different progestins or estrogen doses.
3. Nonoral contraceptive methods, particularly intrauterine systems and implants.

The first layer creates the strongest direct price pressure. The third layer creates the largest long-term substitution risk because it competes on adherence, duration, and convenience rather than price alone.

What generic launch scenarios exist for Aurovela 1.5/30?

Base case

Aurovela remains a mature, multi-source generic with recurring but low-margin volume. Revenue grows mainly through price-neutral volume retention, distribution gains, or temporary competitor shortages. Margin remains constrained.

Upside case

Competitor discontinuations, shortages, or quality actions reduce available supply. Aurobindo captures incremental prescriptions and improves net pricing for a limited period.

Downside case

More suppliers enter, payer contracts shift, or Aurobindo experiences a supply interruption. Volume and price decline, and the product becomes a lower-priority catalog item.

Discontinuation case

If net pricing falls below the cost of maintaining manufacturing, regulatory, and distribution infrastructure, Aurobindo may reduce promotion or discontinue the product despite continued FDA approval.

What is the geographic coverage of Aurovela 1.5/30?

The commercial analysis is primarily U.S.-focused because Aurovela is a U.S. product name and its regulatory and patent position is tied to FDA approval. Aurobindo has a broader international pharmaceutical presence, but equivalent norethindrone acetate/ethinyl estradiol products may be marketed under different names, pack sizes, regulatory approvals, or local distributors.

Geographic expansion would require separate national approvals, local labeling, pharmacovigilance systems, pricing arrangements, and distribution infrastructure. It would not automatically extend U.S. commercial protection or create patent exclusivity.

What patent litigation affects Aurovela 1.5/30?

No significant Aurovela 1.5/30-specific patent litigation is identified in the core public regulatory framework. Litigation risk is low relative to branded drugs and higher-value complex generics.

Potential non-patent disputes could involve:

• Manufacturing quality.
• Product liability.
• Labeling.
• Distribution contracts.
• Recall costs.
• Regulatory compliance.
• Supplier performance.

Those risks can affect financial performance even when patent exposure is minimal.

Key Takeaways

• Aurovela 1.5/30 is a mature generic oral contraceptive containing norethindrone acetate 1.5 mg and ethinyl estradiol 30 mcg.
• Aurobindo Pharma markets the product, but public filings do not disclose product-level revenue or margin.
• The product has no meaningful remaining market exclusivity and no material proprietary patent moat identified.
• Paragraph IV, biosimilar, and branded patent risks are limited.
• The main financial drivers are volume, supply reliability, payer access, manufacturing cost, and generic price competition.
• Temporary upside can arise from competitor shortages or discontinuations.
• Long-term economics are likely low-margin and dependent on portfolio efficiency rather than pricing power.
• Aurovela’s main strategic value is recurring generic volume and distribution utilization, not durable intellectual-property protection.

FAQs About Aurovela 1.5/30

Is Aurovela 1.5/30 the same as Junel 1.5/30?

They contain the same stated active ingredients and strengths, but they are products from different manufacturers. Pharmacy substitution depends on FDA equivalence, state law, payer rules, and dispensing practices.

Does Aurovela 1.5/30 have a patent-protected formulation?

No material product-specific formulation patent protection is publicly identified for the standard immediate-release tablet.

Is Aurovela 1.5/30 a biosimilar?

No. It is a small-molecule generic drug approved through the ANDA pathway, not a biologic approved through the biosimilar pathway.

Can Aurovela 1.5/30 generate significant revenue for Aurobindo?

It can generate recurring revenue, but product-level public data are unavailable. Its mature generic status and direct competition make substantial standalone economic contribution unlikely without a supply disruption or unusually strong market share.

What is the main investment risk linked to Aurovela 1.5/30?

The primary risk is commoditization. Additional suppliers, price erosion, supply interruptions, and portfolio discontinuation are more relevant than patent expiry or Paragraph IV litigation.

References

1. Aurobindo Pharma Limited. (2024). Annual report 2023-24. https://www.aurobindo.com
2. DailyMed. (2024). Aurovela: Norethindrone acetate and ethinyl estradiol tablet, prescribing information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov
3. U.S. Food and Drug Administration. (2025a). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
4. U.S. Food and Drug Administration. (2025b). Drugs@FDA: FDA-approved drugs database. https://www.accessdata.fda.gov/scripts/cder/daf/